Sugi Predict

Sugi Predict / Compounds / SCHEMBL6883030

SCHEMBL6883030

SCHEMBL6883030

CN1CCN(c2cnn(C)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.46
▸ ADRA2C P18825 3/20 0.45
▸ MAPT P10636 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ GFER P55789 1/20 0.45
▸ PTK2B Q14289 1/20 0.45
▸ ESR2 Q92731 1/20 0.45
▸ MELK Q14680 1/20 0.45
▸ HTR3A P46098 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ GLA P06280 1/20 0.42
▸ ACVR1 Q04771 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ ADRA2A P08913 1/20 0.40
▸ CHEK1 O14757 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18107206 0.92 CHKA (0.47) ALDH1A1ADRA2CMAPTGAAKMT2A
SCHEMBL18107430 0.84 CHKA (0.41) ALDH1A1MAPTGAAKMT2AKDM4E
SCHEMBL18107285 0.83 ROCK2 (0.41) ALDH1A1MAPTGAAKMT2AKDM4E
SCHEMBL20009006 0.80 KDM4E (0.49) ALDH1A1MAPTKDM4EACVR1
SCHEMBL6888248 0.80 CHRNA7 (0.52) ALDH1A1ADRA2CMAPTGAAKDM4E
SCHEMBL14701262 0.80 GSK3B (0.33) ALDH1A1MELKHTR3AACVR1
SCHEMBL12065191 0.79 ADRB1 (0.47) HTR3AACVR1
SCHEMBL18107278 0.79 LMNA (0.45) ALDH1A1MAPTGAAKMT2AKDM4E
Hydrochloric Acid SCHEMBL9980600 0.78 ADRB1 (0.46) ALDH1A1KDM4EHTR3AACVR1
SCHEMBL23491301 0.77 KMT2A (0.43) ALDH1A1MAPTKMT2AGFERMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024054469-A1 ISOQUINOLONES AS PI3K INHIBITORS ONKURE, INC. (US) 2024-03-14 — — WO disclosed
EP-3262036-B1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2023-09-13 — — EP disclosed
WO-2023116763-A1 PYRIDAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 上海优理惠生医药有限公司 2023-06-29 — — WO disclosed
WO-2023098825-A1 SOS1 INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF 勤浩医药（苏州）有限公司 2023-06-08 — — WO disclosed
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 — — US disclosed
US-10329263-B2 Disubstituted 1, 2, 4-triazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-25 — — US disclosed
US-10029993-B2 Disubstituted 1, 2, 4-triazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2018-07-24 — — US disclosed
US-10029993-B2 Disubstituted 1, 2, 4-triazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2018-07-24 — — US disclosed
US-9884928-B2 Polymers functionalized with activated nitrogen heterocycles containing a pendant functional group BRIDGESTONE CORPORATION (JP) 2018-02-06 — — US disclosed
US-9738738-B2 Polymers functionalized with activated nitrogen heterocycles containing a pendant functional group BRIDGESTONE CORPORATION (JP) 2017-08-22 — — US disclosed
US-20160289355-A1 POLYMERS FUNCTIONALIZED WITH ACTIVATED NITROGEN HETEROCYCLES CONTAINING A PENDANT FUNCTIONAL GROUP BRIDGESTONE CORPORATION (JP) 2016-10-06 — — US disclosed
WO-2016138114-A1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-09-01 — — WO disclosed
WO-2015163427-A1 NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND 田辺三菱製薬株式会社 2015-10-29 — — WO disclosed
EP-2515656-B1 AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2014-08-06 — — EP disclosed
US-8507494-B2 Heterocyclic quinolizine derived M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2013-08-13 — — US disclosed
US-8383638-B2 Aminobenzoquinazolinone M1 receptor positive allosteric modulators MERCK SHARP & DOHME (US) 2013-02-26 — — US disclosed
US-8383638-B2 Aminobenzoquinazolinone M1 receptor positive allosteric modulators MERCK SHARP & DOHME (US) 2013-02-26 — — US disclosed
US-20120264761-A1 Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME LLC 2012-10-18 — — US disclosed
US-20120264761-A1 Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME LLC 2012-10-18 — — US disclosed
WO-2011084371-A1 AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329263-B2 Disubstituted 1, 2, 4-triazine compound NR3C2, REN, NR5A1 ALDH1A1 68/4885ADRA2C 334/4885MAPT 4335/4885
US-20120264761-A1 Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators CHRM1, OPRL1, MTNR1B ALDH1A1 2379/4885ADRA2C 39/4885MAPT 574/4885
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 ALDH1A1 4081/4885ADRA2C 2129/4885MAPT 1/4885
US-10029993-B2 Disubstituted 1, 2, 4-triazine compound NR3C2, REN, NR5A1 ALDH1A1 68/4885ADRA2C 334/4885MAPT 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.